| [1] | 高英茂. 组织学与胚胎学[M]. 1版. 北京:人民卫生出版社,2001:243-244. | 
																													
																							| [2] | 陈建苏, 徐锦堂. 角膜新生血管[J]. 眼科,2001,10(3):137-143. | 
																													
																							| [3] | 袁检宝. 角膜损伤修复与基质重塑的研究进展[J]. 中华实验眼科杂志,2018,36(4):317-320. | 
																													
																							| [4] | 白军强, 赵世红, 秦海峰,等. 枸橼酸-磷酸氢二钠缓冲液冲洗对小鼠急性角膜化学伤眼表的保护作用[J]. 中华实验眼科杂志,2017,35(2):122-127. | 
																													
																							| [5] | Ueno M, Lyons BL, Burzenski LM, et al. Accelerated wound healing of alkali-burned corneas in MRL mice is associated with a reduced inflammatory signature[J]. Invest Ophthalmol Vis Sci, 2005, 46(11) : 4097-4106. | 
																													
																							| [6] | Antoniotti S, Fiorio Pla A, Pregnolato S, et al. Control of endothelial cell proliferation by calcium influx and arachidonic acid metabolism: a pharmacological approach[J]. J Cell Physiol, 2003, 197(3) : 370-378. | 
																													
																							| [7] | Chang JH, Garg NK, Lunde E, et al. Corneal neovascularization: an anti-VEGF therapy review[J]. Surv Ophthalmol, 2012, 57(5) : 415-429. | 
																													
																							| [8] | 刘子彬, 刘海俊, 封亮旗,等. 不同浓度血管抑素抑制大鼠角膜血管的新生[J]. 中国组织工程研究,2012,16(24):4427-4431. | 
																													
																							| [9] | Voiculescu OB, Voinea LM, Alexandrescu C. Corneal neovascularization and biological therapy[J]. J Med Life, 2015, 8(4) : 444-448. | 
																													
																							| [10] | Roshandel D, Eslani M, Baradaran-Rafii A, et al. Current and upcoming therapies for corneal neovascularization[J]. Ocul Surf, 2018, S1542-0124(18) : 30024-30027. | 
																													
																							| [11] | Hayashi K, Hooper LC, Detrick B, et al. HSV immune complex (HSV-IgG:IC) and HSV-DNA elicit the production of angiogenic factorVEGF and MMP-9[J]. Arch Virol, 2009,154(2) : 219-226. | 
																													
																							| [12] | Abdelfattah NS, Amgad M, Zayed AA, et al. Clinical correlates of common corneal neovascular diseases: a literature review[J]. Int J Ophthalmol, 2015, 8(1) : 182-193. | 
																													
																							| [13] | Whitcher JP, Srinivasan M, Upadhyay MP. Corneal blindness: a global perspective[J]. Bull World Health Organ, 2001, 79(3) : 214-221. | 
																													
																							| [14] | Hilber D, Mitchener TA, Stout J, et al. Eye injury surveillance in the U.S. Department of Defense, 1996-2005[J]. Am J Prev Med, 2010, 38(1 Suppl) : S78-85. | 
																													
																							| [15] | Kumar J, Gehra A, Sirohi N. Role of Frequency Doubled Nd: Yag Laser in Treatment of Corneal Neovascularisation[J]. J Clin Diagn Res, 2016, 10(4) : NC01-NC04. | 
																													
																							| [16] | Al-Torbak AA. Photodynamic therapy with verteporfin for corneal neovascularization[J]. Middle East Afr J Ophthalmol, 2012, 19(2) : 185-189. | 
																													
																							| [17] | Stevenson W, Cheng SF, Dastjerdi MH,et al.Corneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)[J]. Ocul Surf, 2012, 10(2) : 67-83. | 
																													
																							| [18] | 黄玉庚, 王铜亮, 王涛,等. 雷珠单抗治疗老年人角膜新生血管的临床疗效[J]. 中华老年医学杂志,2017,36(6):683-686. | 
																													
																							| [19] | 温舒, 杨炜. 角膜新生血管治疗的研究现状[J]. 国际眼科纵览,2017,41(1):43-47. | 
																													
																							| [20] | 代震宇, 李立. 角膜新生血管治疗的研究进展[J]. 国际眼科杂志,2006,6(4):844-847. | 
																													
																							| [21] | George PM, Wells AU. Pirfenidone for the treatment of idiopathic pulmonary fibrosis[J]. Expert Rev Clin Pharmacol, 2017, 10(5) : 483-491. | 
																													
																							| [22] | 付麟紫, 吴晓梅. 特发性肺纤维化药物治疗推荐[J]. 中华老年多器官疾病杂志,2017,16(3):234-237. | 
																													
																							| [23] | 陈钰清, 闫永吉, 仇美华,等. 吡非尼酮治疗肺纤维化的疗效与安全性meta分析[J]. 临床药物治疗杂志,2016,14(4):13-22. | 
																													
																							| [24] | Owens GM. Strategies to manage costs in idiopathic pulmonary fibrosis[J].Am J Manag Care, 2017, 23(11 Suppl) : S191-S196. | 
																													
																							| [25] | Tzouvelekis A, Bouros E, Tzilas V, et al. Pirfenidone in Idiopathic Pulmonary Fibrosis " RECAP-itulating Safety into the Real World" [J]. Respiration, 2017, 94(5) : 405-407. | 
																													
																							| [26] | 徐建华, 肖红波, 程玉花,等. 吡非尼酮对大鼠肾间质纤维化的防治作用研究[J]. 中国现代医学杂志,2017,27(19):1-6. | 
																													
																							| [27] | 肖敏, 屈小虎, 吕聚坪,等. 吡非尼酮对四氯化碳诱导的小鼠肝纤维化的影响[J]. 中国应用生理学杂志,2016,32(4):378-382. | 
																													
																							| [28] | George PM, Wells AU. Pirfenidone for the treatment of idiopathic pulmonary fibrosis[J]. Expert Rev Clin Pharmacol, 2017, 10(5) : 483-491. | 
																													
																							| [29] | Tzouvelekis A, Ntolios P, Karampitsakos T, et al. Safety and efficacy of pirfenidone in severe Idiopathic Pulmonary Fibrosis a real-world observational study[J]. Pulm Pharmacol Ther, 2017, 46(8) : 48-53. | 
																													
																							| [30] | 王红梅, 杨佳丹, 蒙龙,等. 吡非尼酮治疗特发性肺纤维化疗效与安全性的系统评价[J]. 中国药房,2016,27(3):345-348. | 
																													
																							| [31] | 付麟紫, 吴晓梅. 特发性肺纤维化药物治疗推荐[J]. 中华老年多器官疾病杂志,2017,16(3):234-237. | 
																													
																							| [32] | Schaefer CJ, Ruhrmund DW, Pan L, et al. Antifibrotic activities of pirfenidone in animal models[J]. Eur Respir Rev, 2011, 20(120) : 85-97. | 
																													
																							| [33] | 杜磊, 王昌源, 张立华,等. 吡非尼酮对实验性大鼠肝纤维化的作用[J]. 山东大学学报(医学版),2009,47(11):50-54. | 
																													
																							| [34] | 王琳娜, 陈常勇, 郭存霞,等. 吡非尼酮对转化生长因子-β1诱导的大鼠心肌成纤维细胞增殖和胶原蛋白合成的影响[J]. 中国现代医学杂志,2015,25(29):30-34. | 
																													
																							| [35] | 姬巍, 蒋恒, 杨伟志,等. 吡非尼酮防治放射性肺纤维化实验研究[J]. 中华放射肿瘤学杂志,2010,19(6):560-563. | 
																													
																							| [36] | Tian XL, Yao W, Guo ZJ,et al. Low dose pirfenidone suppresses transforming growth factor beta-1 and tissue inhibitor of metalloproteinase-1, and protects rats from lung fibrosis induced by bleomycina[J]. Chin Med Sci J, 2006, 21(3) : 145-151. | 
																													
																							| [37] | Waller JR, Murphy GJ, Bicknell GR, et al. Pirfenidone inhibits early myointimal proliferation but has no effect on late lesion size in rats[J]. Eur J Vasc Endovasc Surg, 2002, 23(3) : 234-240. | 
																													
																							| [38] | Papathanassiou M, Theodossiadis PG, Liarakos VS,et al. Inhibition of corneal neovascularization by subconjunctival bevacizumab in an animal model[J]. Am J Ophthalmol, 2008, 145(3) : 424-431. | 
																													
																							| [39] | Gupta D, Illingworth C.Treatments for corneal neovascularization: a review[J].Cornea, 2011, 30(8) : 927-938. | 
																													
																							| [40] | Fujita S, Saika S, Kao WW,et al.Endogenous TNFalpha suppression of neovascularization in corneal stroma in mice[J]. Invest Ophthalmol Vis Sci, 2007, 48(7) : 3051-3055. | 
																													
																							| [41] | 陈俊杰, 吴共发, 林俊汕,等. 吡非尼酮对大鼠角膜基质细胞增殖的影响[J]. 国际眼科杂志,2015,15 (2):201-204. | 
																													
																							| [42] | 吴共发, 邱丽浈, 黄绮亭,等. 吡非尼酮抑制转化生长因子β1诱导的大鼠角膜基质细胞纤维化[J]. 实用医学杂志,2018,34(12):1955-1958. | 
																													
																							| [43] | 邹志康, 吴共发, 邱丽浈,等. 吡非尼酮滴眼液对大鼠角膜急性碱烧伤后瘢痕的作用研究[J]. 中国临床药理学与治疗学,2018,23(8):881-885. | 
																													
																							| [44] | 吴共发, 邱丽浈, 曾宇婷,等. 自制吡非尼酮滴眼液局部应用于角膜的安全性研究[J/CD]. 中华眼科医学杂志(电子版),2017,7(6):250-256. | 
																													
																							| [45] | 王淑荣, 田舒慈, 刘鑫,等. 制备角膜新生血管动物模型的研究进展[J]. 国际眼科杂志,2015,15(11):1892-1895. | 
																													
																							| [46] | Shi H, Yu HJ, Wang HY, et al. Topical administration of peroxiredoxin-6 on the cornea suppresses inflammation and neovascularization induced by ultraviolet radiation[J]. Invest Ophthalmol Vis Sci, 2012, 53(13) : 8016-8028. | 
																													
																							| [47] | Gurudutta U, Vimal K, Yogesh K,et al. Hematopoietic Stem Cell Antigen CD34: Role in Adhesion or Homing[J]. Stem Cells and Dev, 2006, 15(3) : 305-313. | 
																													
																							| [48] | 程继荣, 徐虓, 王淑琴,等. 肺癌组织CD31、CD34及CD105标记的微血管密度的临床意义[J]. 中国癌症杂志,2010,20(8):638-640. | 
																													
																							| [49] | 黄如林, 梁杰, 夏琼平,等. CD34及CD105两种微血管标记物在瘢痕微血管构筑中的比较[J]. 中国组织工程研究与临床康复,2011,15(11):1977-1980. | 
																													
																							| [50] | 李小静, 盂刚. 瘢痕微血管构筑的研究进展[J]. 中国临床康复,2002,6(4):480-481. |